PureTech Health (LON:PRTC) Stock Price Passes Below Two Hundred Day Moving Average – Time to Sell?

PureTech Health plc (LON:PRTC) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 126.05 and traded as low as GBX 114. PureTech Health shares last traded at GBX 117.40, with a volume of 3,148,794 shares traded.

Wall Street Analyst Weigh In

Separately, Peel Hunt restated a “buy” rating and issued a GBX 508 target price on shares of PureTech Health in a research note on Monday, July 13th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of GBX 508.

PureTech Health Stock Performance

The firm has a market cap of £285.77 million, a price-to-earnings ratio of -2.55 and a beta of 0.77. The stock’s fifty day moving average is GBX 125.17 and its two-hundred day moving average is GBX 126.05. The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59.

Insider Buying and Selling

In other PureTech Health news, insider John LaMattina acquired 93,944 shares of PureTech Health stock in a transaction dated Wednesday, July 29th. The stock was acquired at an average cost of GBX 1 per share, for a total transaction of £939.44. Also, insider Sharon Barber-Lui acquired 93,944 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average cost of GBX 1 per share, with a total value of £939.44. Insiders have acquired 617,569 shares of company stock valued at $18,063,751 in the last ninety days. Insiders own 13.41% of the company’s stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.